Perfect the design of your value added services on a case-by-case, disease-specific basis
Oct 8, 2014
Matthew Bonam, Project Director at AstraZeneca, talks about the continuing success of AstraZeneca's Intelligent Pharmaceuticals initiative, and explains the need to go beyond just providing pills and to manage disease with a true understanding of therapeutic area pathways, while avoiding the pitfalls of a 'me-too' value added service.
This content is premium content, and only accessible to Premium members. Get On Demand now